Implementing the Vision for Toxicity Testing in the 21st Century:

If You Build It, Will They Come?

Timothy Malloy
UCLA School of Law
UCLA Fielding School of Public Health

Where We Are Headed


Survey Background

Socio-Legal Barriers to Adoption

Socio-Legal Drivers of Adoption

Conclusions

The Survey



Methods and Applications

Methods

Quantitative Structure Activity Relationship (QSAR)

Mechanistically based *in vitro* assays

Mechanistically based *in vivo* assays

High throughput *in vitro* assays

High throughput in vivo assays

Biomarkers

Applications

Screening/prioritization for further testing

Screening/prioritization for other actions (e.g. risk assessment, risk management)

Setting doses for in vivo testing

Weight of evidence in quantitative risk assessment (scoping to determine most sensitive endpoints)

Qualitative risk assessment (e.g., control banding)

Quantitative risk assessment (identifying NOAEL or other levels)


Comparative assessment of alternative chemicals/products/processes (alternatives analysis)

Use and Viability


| Technology | Mech in vitro | HTS in vitro | Mech in vivo | HTS in vivo | QSARs | Bio- markers |
|---------------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|---------------------------------------------------------------|-----------------|
| Use | | | | | | |
| Screening/prioritization for further testing | 83.9% (1.2%) | 81.6% (1.3%) | 74.2% (1.6%) | 70.1% (1.7%) | 86.4% (1.1%) | 82.5% (1.3%) |
| Screening/prioritization for other actions | 71.7% | 67.7% | 64.4% | 59.2% | 76.6% | 77.0% |
| | (1.5%) | (1.6%) | (1.7%) | (1.8%) | (1.4%) | (1.4%) |
| Comparative assessment of alternative chemicals | 65.9% | 58.0% | 57.9% | 53.2% | 69.2% | 68.5% |
| | (1.7%) | (1.8%) | (1.8%) | (1.9%) | (1.6%) | (1.7%) |
| Weight of evidence in quantitative risk assessment | 58.8% | 47.1% | 52.1% | 41.1% | 64.6% | 68.8% |
| | (1.7%) | (1.8%) | (1.8%) | (1.9%) | (1.6%) | (1.6%) |
| Qualitative risk assessment | 55.9% | 45.2% | 51.4% | 43.1% | 62.6% | 67.0% |
| | (1.8%) | (1.9%) | (2.0%) | (2.0%) | (1.8%) | (1.8%) |
| Setting doses for in vivo testing | 49.8% | 36.9% | 45.3% | 38.0% | 52.6% | 63.9% |
| | (1.7%) | (1.7%) | (1.8%) | (1.8%) | (1.7%) | (1.7%) |
| Setting NOAEL or other levels in quantitative risk assessment | 32.8% (1.7%) | 25.5% (1.6%) | 33.0% (1.7%) | 26.9% (1.7%) | $\left(\begin{array}{c} 42.8\% \\ (1.7\%) \end{array}\right)$ | 53.5% (1.8%) |

Least viable Most viable

Socio-Legal Barriers



Socio-Legal Drivers



The Role of TSCA Reform

- Explicit provisions regarding alternative methods create positive context
 - Create "soft" mandate for alternative methods for screening
 - Mandate planning and evaluation of alternative methods
- Provision do not address certain institutional barriers
 - Organizational Inertia
 - Slow Validation

The Team



Patrick Allard Pl. ISG, FSPH



Tim Malloy
PI. UCLA Law school, FSPH
STPP



Virginia Zaunbrecher
Director of Programs and
Outreach, STPP



Donatello Telesco



Joseph Doherty
UCLA Law School



Fellow Public Affairs



Daniela Parodi Fellow ISG



Steven ShaferGraduate Student. Law

Funding from:

UCLA Institute of the Environment and Sustainability
Office of the UCLA Vice Chancellor for Research

